Physician profile
Arturo E Blanco
NPI 1184778508
$8,971.84
in general payments reported to CMS, 2019-2025
39 companies · $892 in 2025
The $892 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $1,515 · 2021: $1,336 · 2022: $1,190 · 2023: $1,652 · 2024: $916 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,215.18 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $1,205.77 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Lilly USA, LLC | $1,043.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $953.52 | 2019-2025 | |
| Abbvie INC. | $632.14 | 2019-2025 | Vraylar, Ubrelvy |
| Merck Sharp & Dohme LLC | $463.25 | 2019-2023 | Verquvo, Belsomra |
| Amgen INC. | $446.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $379.60 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.50 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $313.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $281.21 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $277.33 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $191.84 | 2021-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $172.45 | 2019-2023 | Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $171.39 | 2023-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.